AIM ImmunoTech Aktie - AIM

Professionelle Tools für Privatanleger.

Premium

Current Price

0,1277

Gebot

Fragen

Volumen

287.732

0,1215 Tagesbereich 0,135

0,1105 52-Wochen-Bereich 0,62

Marktkapitalisierung

8,135M

Handelsende

0,125

Handelsbeginn

0,135

Letzte Trade

500

0.1234

Letzter Handelszeitpunkt

Finanzvolumen

US$ 36.125

VWAP

0,125552

Durchschnittliches Volumen (3 Mio.)

1.106.230

Ausgegebene Aktien

63.706.446

Dividendenrendite

Kurs-Gewinn-Verhältnis

-3,96

Gewinn pro Aktie (EPS)

-0,45

Erlöse

202k

Nettogewinn

-28,96M

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alfero... AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19. Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.aimimmuno.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

AIM ImmunoTech Inc is listed in the Biological Pds,ex Diagnstics sector of the Amerikanische Börse with ticker AIM. The last closing price for AIM ImmunoTech was US$0,13. Over the last year, AIM ImmunoTech shares have traded in a share price range of US$ 0,1105 to US$ 0,62.

AIM ImmunoTech currently has 63.706.446 shares in issue. The market capitalisation of AIM ImmunoTech is US$7,96 million. AIM ImmunoTech has a price to earnings ratio (PE ratio) of -3.96.

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical...

Form 4 - Statement of changes in beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form 8-K - Current report

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.0041	3.31715210356	0.1236	0.142	0.1153	916150	0.12955218	CS
4	-0.0223	-14.8666666667	0.15	0.16	0.1105	1175094	0.13350172	CS
12	-0.0773	-37.7073170732	0.205	0.254	0.1105	1106230	0.16310856	CS
26	-0.1823	-58.8064516129	0.31	0.3267	0.1105	738193	0.18742401	CS
52	-0.2306	-64.3594753	0.3583	0.62	0.1105	501083	0.24693337	CS
156	-0.7323	-85.1511627907	0.86	1.38	0.1105	296004	0.46765214	CS
260	-4.6223	-97.3115789474	4.75	5.5	0.1105	1059489	2.15962971	CS

AIM - Frequently Asked Questions (FAQ)

What is the current AIM ImmunoTech share price?

The current share price of AIM ImmunoTech is US$ 0,1277

How many AIM ImmunoTech shares are in issue?

AIM ImmunoTech has 63.706.446 shares in issue

What is the market cap of AIM ImmunoTech?

The market capitalisation of AIM ImmunoTech is USD 7,96M

What is the 1 year trading range for AIM ImmunoTech share price?

AIM ImmunoTech has traded in the range of US$ 0,1105 to US$ 0,62 during the past year

What is the PE ratio of AIM ImmunoTech?

The price to earnings ratio of AIM ImmunoTech is -3,96

What is the cash to sales ratio of AIM ImmunoTech?

The cash to sales ratio of AIM ImmunoTech is 562,5

What is the reporting currency for AIM ImmunoTech?

AIM ImmunoTech reports financial results in USD

What is the latest annual turnover for AIM ImmunoTech?

The latest annual turnover of AIM ImmunoTech is USD 202k

What is the latest annual profit for AIM ImmunoTech?

The latest annual profit of AIM ImmunoTech is USD -28,96M

What is the registered address of AIM ImmunoTech?

The registered address for AIM ImmunoTech is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the AIM ImmunoTech website address?

The website address for AIM ImmunoTech is www.aimimmuno.com

Which industry sector does AIM ImmunoTech operate in?

AIM ImmunoTech operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
BURUNuburu Inc	US$ 0,2202 (29,53%)	115,62M
ASMAvino Silver and Gold Mines Ltd	US$ 1,7151 (21,64%)	7,95M
SATXSatixFy Communications Ltd	US$ 1,39 (19,83%)	2,82M
AMBIAmbipar Emergency Response	US$ 4,31 (15,76%)	52,88k
TSLTT Rex 2X Long Tesla Daily Target ETF	US$ 12,47 (15,14%)	8,25M
IBOImpact Biomedical Inc	US$ 0,6642 (-21,86%)	190,99k
KNWKnow Labs Inc	US$ 1,91 (-16,96%)	81,38k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 5,065 (-15,02%)	74,88M
BOILProShares Ultra Bloomberg Natural Gas New	US$ 86,63 (-14,09%)	1,24M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3,42 (-12,76%)	50,94M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 18,30 (5,11%)	137,65M
BURUNuburu Inc	US$ 0,2202 (29,53%)	115,62M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 4,83 (1,68%)	109,2M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 7,29 (-1,62%)	104,63M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 5,065 (-15,02%)	74,88M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

AIM ImmunoTech Inc (AIM) Börsenkurse

AIM ImmunoTech Inc (AIM)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über AIM ImmunoTech Inc

AIM Neueste Nachrichten

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Form 8-K - Current report

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen